Citrulline in Severe Sepsis
| Status: | Recruiting |
|---|---|
| Conditions: | Hospital, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | 13 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2012 |
Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous Citrulline to Prevent or Mitigate Acute Lung Injury in Patients With Severe Sepsis
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate
biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to
placebo in patients with severe sepsis at risk for or with acute lung injury. The hypothesis
is that intravenous L-citrulline will decreased the development or progression of acute lung
injury in patients with severe sepsis compared to placebo.
biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to
placebo in patients with severe sepsis at risk for or with acute lung injury. The hypothesis
is that intravenous L-citrulline will decreased the development or progression of acute lung
injury in patients with severe sepsis compared to placebo.
Inclusion Criteria:
- Severe Sepsis
Exclusion Criteria:
- No Consent
- Malignant or other irreversible condition
- Moribund and not expected to survive 48 hours
- End Stage Liver Disease
- Enrolled in another IND study
- Pregnant or breast feeding female
- Age<13 years old
- Allergy to citrulline or arginine
We found this trial at
1
site
2201 West End Ave
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-7311
Principal Investigator: Todd Rice, MD
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
Click here to add this to my saved trials
